The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Lee M. Krug

Thoracic Oncology Service

Memorial Sloan-Kettering Cancer Center

Weill Medical College of Cornell University

1275 York Ave.

USA

[email]@mskcc.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Ave., USA. 2012
  • Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York City, New York, USA. 2009 - 2011
  • Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, USA. 2000 - 2007

References

  1. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Krug, L.M., Ragupathi, G., Hood, C., George, C., Hong, F., Shen, R., Abrey, L., Jennings, H.J., Kris, M.G., Livingston, P.O. Cancer Immunol. Immunother. (2012) [Pubmed]
  2. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. Krug, L.M., Crawford, J., Ettinger, D.S., Shapiro, G.I., Spigel, D., Reiman, T., Temel, J.S., Michelson, G.C., Young, D.Y., Hoch, U., Adelman, D.C. J. Thorac. Oncol (2011) [Pubmed]
  3. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Krug, L.M., Dao, T., Brown, A.B., Maslak, P., Travis, W., Bekele, S., Korontsvit, T., Zakhaleva, V., Wolchok, J., Yuan, J., Li, H., Tyson, L., Scheinberg, D.A. Cancer Immunol. Immunother. (2010) [Pubmed]
  4. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. Krug, L.M., Pass, H.I., Rusch, V.W., Kindler, H.L., Sugarbaker, D.J., Rosenzweig, K.E., Flores, R., Friedberg, J.S., Pisters, K., Monberg, M., Obasaju, C.K., Vogelzang, N.J. J. Clin. Oncol. (2009) [Pubmed]
  5. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. Krug, L.M., Heelan, R.T., Kris, M.G., Venkatraman, E., Sirotnak, F.M. J. Thorac. Oncol (2007) [Pubmed]
  6. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. Krug, L.M., Milton, D.T., Jungbluth, A.A., Chen, L.C., Quaia, E., Pandit-Taskar, N., Nagel, A., Jones, J., Kris, M.G., Finn, R., Smith-Jones, P., Scott, A.M., Old, L., Divgi, C. J. Thorac. Oncol (2007) [Pubmed]
  7. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Krug, L.M., Curley, T., Schwartz, L., Richardson, S., Marks, P., Chiao, J., Kelly, W.K. Clin. Lung. Cancer (2006) [Pubmed]
  8. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Krug, L.M., Crapanzano, J.P., Azzoli, C.G., Miller, V.A., Rizvi, N., Gomez, J., Kris, M.G., Pizzo, B., Tyson, L., Dunne, M., Heelan, R.T. Cancer (2005) [Pubmed]
  9. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. Krug, L.M., Miller, V.A., Patel, J., Crapanzano, J., Azzoli, C.G., Gomez, J., Kris, M.G., Heelan, R.T., Pizzo, B., Tyson, L., Sheehan, C., Ross, J.S., Venkatraman, E. Cancer (2005) [Pubmed]
  10. An overview of chemotherapy for mesothelioma. Krug, L.M. Hematol. Oncol. Clin. North Am. (2005) [Pubmed]
  11. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Krug, L.M., Ragupathi, G., Hood, C., Kris, M.G., Miller, V.A., Allen, J.R., Keding, S.J., Danishefsky, S.J., Gomez, J., Tyson, L., Pizzo, B., Baez, V., Livingston, P.O. Clin. Cancer Res. (2004) [Pubmed]
  12. Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Krug, L.M., Miller, V.A., Filippa, D.A., Venkatraman, E., Ng, K.K., Kris, M.G. Lung. Cancer (2003) [Pubmed]
  13. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Krug, L.M., Azzoli, C.G., Kris, M.G., Miller, V.A., Khokhar, N.Z., Tong, W., Ginsberg, M.S., Venkatraman, E., Tyson, L., Pizzo, B., Baez, V., Ng, K.K., Sirotnak, F.M. Clin. Cancer Res. (2003) [Pubmed]
  14. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Krug, L.M., Ng, K.K., Kris, M.G., Miller, V.A., Tong, W., Heelan, R.T., Leon, L., Leung, D., Kelly, J., Grant, S.C., Sirotnak, F.M. Clin. Cancer Res. (2000) [Pubmed]
 
WikiGenes - Universities